Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
side by side viewer icon HTML

Abstract

Ubiquitous expression patterns of nuclear hormone and their receptors (NHRs) have their own roles in performing essential functions in controlling hormone responsive element-promoted gene transcription. In diseased states such as cancer, NHRs play crucial roles and hence targeting these receptors are essential as it gives us a window of opportunity for developing targeted anticancer therapeutics. In comparison to traditional chemotherapy drugs, targeted therapeutic drugs are hypothetically advantageous in terms of efficacy and safety and hence the idea of developing such targeted drugs are inclined to become a mainstream cancer treatment option. This review selectively compiles data regarding NHR-targeting, while majorly focusing on cancer treatment using anticancer small molecules and/or nanotherapeutics targeting estrogen receptor, progesterone receptor, glucocorticoid receptor, and vitamin D receptor. In this study, we selectively emphasized on estrogen receptor. Herein, we mainly highlight the strategy of lipid-modification to convert respective receptor ligands into NHR-targeted anticancer molecules as well as nanotherapeutics. We focused on the strategy of chemical conjugation of those ligands with twin-aliphatic carbon chain-based cationic lipids. The strategy successfully led to the development of a new class of anticancer therapeutics. These are either small-molecule anticancer agents or self-aggregating nanotherapeutics. In spite of great anticancer output, the concept of NHR-targeted anti-cancer therapy still needs to overcome further hurdles before those are projected for clinical settings.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X314913240909071917
2024-09-18
2025-03-01

  • From This Site

    /content/journals/cis/10.2174/012210299X314913240909071917
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. BedardP.L. HymanD.M. DavidsM.S. SiuL.L. Small molecules, big impact: 20 years of targeted therapy in oncology.Lancet2020395102291078108810.1016/S0140‑6736(20)30164‑132222192
     [Google Scholar]
  2. ZhongL. LiY. XiongL. WangW. WuM. YuanT. YangW. TianC. MiaoZ. WangT. YangS. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.Signal Transduct. Target. Ther.20216120110.1038/s41392‑021‑00572‑w34054126
     [Google Scholar]
  3. MahadikN. BhattacharyaD. PadmanabhanA. SakhareK. NarayanK.P. BanerjeeR. Targeting steroid hormone receptors for anti-cancer therapy: A review on small molecules and nanotherapeutic approaches.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.2022142e175510.1002/wnan.175534541822
     [Google Scholar]
  4. ZhaoL. ZhouS. GustafssonJ.Å. Nuclear receptors: recent drug discovery for cancer therapies.Endocr. Rev.20194051207124910.1210/er.2018‑0022230869771
     [Google Scholar]
  5. KarmaliP.P. ChaudhuriA. Cationic liposomes as non-viral carriers of gene medicines: Resolved issues, open questions, and future promises.Med. Res. Rev.200727569672210.1002/med.2009017022036
     [Google Scholar]
  6. FelgnerP.L. GadekT.R. HolmM. RomanR. ChanH.W. WenzM. NorthropJ.P. RingoldG.M. DanielsenM. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.Proc. Natl. Acad. Sci. USA198784217413741710.1073/pnas.84.21.74132823261
     [Google Scholar]
  7. Girão da CruzM.T. SimõesS. PiresP.P.C. NirS. Pedroso de LimaM.C. Kinetic analysis of the initial steps involved in lipoplex–cell interactions: effect of various factors that influence transfection activity.Biochim. Biophys. Acta Biomembr.200115101-213615110.1016/S0005‑2736(00)00342‑411342154
     [Google Scholar]
  8. LonezC. VandenbrandenM. RuysschaertJ.M. Cationic lipids activate intracellular signaling pathways.Adv. Drug Deliv. Rev.201264151749175810.1016/j.addr.2012.05.00922634161
     [Google Scholar]
  9. a AramakiY. TakanoS. TsuchiyaS. Induction of apoptosis in macrophages by cationic liposomes.FEBS Lett.1999460347247610.1016/S0014‑5793(99)01386‑110556519
     [Google Scholar]
  10. b AramakiY. TakanoS. ArimaH. TsuchiyaS. Induction of apoptosis in WEHI 231 cells by cationic liposomes.Pharm. Res.200017551552010.1023/A:100755252928010888301
     [Google Scholar]
  11. OualiM. RuysschaertJ.M. LonezC. VandenbrandenM. Cationic lipids involved in gene transfer mobilize intracellular calcium.Mol. Membr. Biol.200724322523210.1080/0968786060110891117520479
     [Google Scholar]
  12. KusumotoK. IshikawaT. Didodecyldimethylammonium bromide (DDAB) induces caspase-mediated apoptosis in human leukemia HL-60 cells.J. Control. Release2010147224625210.1016/j.jconrel.2010.07.11420674638
     [Google Scholar]
  13. SinhaS. RoyS. ReddyB.S. PalK. SudhakarG. IyerS. DuttaS. WangE. VohraP.K. RoyK.R. ReddannaP. MukhopadhyayD. BanerjeeR. A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis.Mol. Cancer Res.20119336437410.1158/1541‑7786.MCR‑10‑052621289296
     [Google Scholar]
  14. PalK. PoreS. SinhaS. JanardhananR. MukhopadhyayD. BanerjeeR. Structure-activity study to develop cationic lipid-conjugated haloperidol derivatives as a new class of anticancer therapeutics.J. Med. Chem.20115472378239010.1021/jm101530j21391684
     [Google Scholar]
  15. MuktapuramP.R. GaraR.K. SharmaK. RohitC. SrinivasK. MishraD.P. BathulaS.R. Anticancer siRNA delivery by new anticancer molecule: A novel combination strategy for cancer cell killing.Eur. J. Med. Chem.20125640040810.1016/j.ejmech.2012.07.03522926227
     [Google Scholar]
  16. WangW. BaiZ. ZhangF. WangC. YuanY. ShaoJ. Synthesis and biological activity evaluation of emodin quaternary ammonium salt derivatives as potential anticancer agents.Eur. J. Med. Chem.20125632033110.1016/j.ejmech.2012.07.05122921966
     [Google Scholar]
  17. FojoT. ParkinsonD.R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?Clin. Cancer Res.201016245972598010.1158/1078‑0432.CCR‑10‑127721169250
     [Google Scholar]
  18. FisherB. DignamJ. BryantJ. DeCillisA. WickerhamD.L. WolmarkN. CostantinoJ. RedmondC. FisherE.R. BowmanD.M. DeschênesL. DimitrovN.V. MargoleseR.G. RobidouxA. ShibataH. TerzJ. PatersonA.H.G. FeldmanM.I. FarrarW. EvansJ. LickleyH.L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.J. Natl. Cancer Inst.199688211529154210.1093/jnci/88.21.15298901851
     [Google Scholar]
  19. PalA. GangulyA. GhoshA. YousufM. RathoreB. BanerjeeR. AdhikariS. Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor.ChemMedChem20149472773210.1002/cmdc.20140000324482362
     [Google Scholar]
  20. AriaziE. AriaziJ. CorderaF. JordanV. Estrogen receptors as therapeutic targets in breast cancer.Curr. Top. Med. Chem.20066318120210.2174/15680260677617348316515478
     [Google Scholar]
  21. LafrontC. GermainL. WeidmannC. Audet-WalshÉ. A systematic study of the impact of estrogens and selective estrogen receptor modulators on prostate cancer cell proliferation.Sci. Rep.2020101402410.1038/s41598‑020‑60844‑332132580
     [Google Scholar]
  22. Lewis-WambiJ.S. KimH. CurpanR. GriggR. SarkerM.A. JordanV.C. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.Mol. Pharmacol.201180461062010.1124/mol.111.07224921737572
     [Google Scholar]
  23. LargeD.E. SoucyJ.R. HebertJ. AugusteD.T. Advances in receptor-mediated, tumor-targeted drug delivery.Adv. Ther. (Weinh.)201921180009110.1002/adtp.20180009138699509
     [Google Scholar]
  24. ThakurV. KuttyR.V. Recent advances in nanotheranostics for triple negative breast cancer treatment.J. Exp. Clin. Cancer Res.201938143010.1186/s13046‑019‑1443‑131661003
     [Google Scholar]
  25. MannaS. HolzM. K. Tamoxifen action in ER-negative breast cancer.Sign Transduct Insights.201651710.4137/STI.S29901
     [Google Scholar]
  26. AndeyT. SudhakarG. MarepallyS. PatelA. BanerjeeR. SinghM. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.Mol. Pharm.20151241105112010.1021/mp500862925661724
     [Google Scholar]
  27. SudhakarG. BathulaS.R. BanerjeeR. Development of new estradiol-cationic lipid hybrids: Ten-carbon twin chain cationic lipid is a more suitable partner for estradiol to elicit better anticancer activity.Eur. J. Med. Chem.20148665366310.1016/j.ejmech.2014.09.03025222876
     [Google Scholar]
  28. YousufM. SridharanK. MishraT. MahadikN.S. BanerjeeR. AdhikariS.S. Cationic lipid-conjugated bis-arylidene oxindole derivatives as broad-spectrum breast cancer-selective therapeutics.Bioorg. Chem.202313310639510.1016/j.bioorg.2023.10639536753964
     [Google Scholar]
  29. YousufM. JinkaS. AdhikariS.S. BanerjeeR. Methoxy-enriched cationic stilbenes as anticancer therapeutics.Bioorg. Chem.20209810371910.1016/j.bioorg.2020.10371932171988
     [Google Scholar]
  30. RoyS. ReddyB.S. SudhakarG. KumarJ.M. BanerjeeR. 17β-estradiol-linked nitro-L-arginine as simultaneous inducer of apoptosis in melanoma and tumor-angiogenic vascular endothelial cells.Mol. Pharm.20118235035910.1021/mp200034621291219
     [Google Scholar]
  31. KalaR. TollefsbolT.O. A novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-α (ERα) expression in ERα-negative breast cancer cells.PLoS One2016115e015505710.1371/journal.pone.015505727159275
     [Google Scholar]
  32. BaylissJ. HilgerA. VishnuP. DiehlK. El-AshryD. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.Clin. Cancer Res.200713237029703610.1158/1078‑0432.CCR‑07‑058718056179
     [Google Scholar]
  33. PufallM.A. Glucocorticoids and cancer.Glucocorticoid Signaling: From Molecules to Mice to Man2015315333
     [Google Scholar]
  34. AndersenJ.C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy.N. Engl. J. Med.1994330221560156410.1056/NEJM1994060233022038177245
     [Google Scholar]
  35. GangulyA. RachamallaH.K.R. BhattacharyaD. BhamidipatiK. PalA. Gora RavuriH. ChakravartyS. AdhikariS.S. BanerjeeR. Oestrogen receptor-mediated liposomal drug delivery for treating melanoma.J. Drug Target.2018265-648149310.1080/1061186X.2018.143367929376759
     [Google Scholar]
  36. SauS. BanerjeeR. Cationic lipid-conjugated dexamethasone as a selective antitumor agent.Eur. J. Med. Chem.20148343344710.1016/j.ejmech.2014.06.05124992071
     [Google Scholar]
  37. SauS. MondalS.K. KashawS.K. IyerA.K. BanerjeeR. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.Mol. Cell. Biochem.20174361-211913610.1007/s11010‑017‑3084‑z28585089
     [Google Scholar]
  38. RathoreB. Chandra Sekhar JaggarapuM.M. GangulyA. Reddy RachamallaH.K. BanerjeeR. Cationic lipid-conjugated hydrocortisone as selective antitumor agent.Eur. J. Med. Chem.201610830932110.1016/j.ejmech.2015.11.03326695732
     [Google Scholar]
  39. SridharanK. RathoreB. YousufM. Reddy RachamallaH.K. JinkaS. JaggarapuM.M.C.S. BanerjeeR. Self-assembling derivative of hydrocortisone as glucocorticoid receptor-targeted nanotherapeutics for synergistic, combination therapy against colorectal tumor.Mol. Pharm.20211831208122810.1021/acs.molpharmaceut.0c0109133371687
     [Google Scholar]
  40. MondalS.K. JinkaS. BanerjeeR. Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof.European Patent EP3275888A12018
  41. RachamallaH.K. VoshavarC. ArjunanP. MahalingamG. ChowathR.P. BanerjeeR. VemulaP.K. MarepallyS. Skin-permeable nano-lithocholic lipidoid efficiently alleviates psoriasis-like chronic skin inflammations.ACS Appl. Mater. Interfaces20221413148591487010.1021/acsami.1c1918035347979
     [Google Scholar]
  42. MukherjeeA. NarayanK.P. PalK. KumarJ.M. RangarajN. KalivendiS.V. BanerjeeR. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor.Mol. Ther.200917462363110.1038/mt.2009.419223869
     [Google Scholar]
  43. FolkerdE.J. DowsettM. Influence of sex hormones on cancer progression.J. Clin. Oncol.201028264038404410.1200/JCO.2009.27.429020644089
     [Google Scholar]
  44. DanielA.R. HaganC.R. LangeC.A. Progesterone receptor action: defining a role in breast cancer.Expert Rev. Endocrinol. Metab.20116335936910.1586/eem.11.2521857868
     [Google Scholar]
  45. SchmidtM. BremerE. HasencleverD. VictorA. GehrmannM. SteinerE. SchifferI.B. GebhardtS. LehrH-A. MahlkeM. HermesM. MusteaA. TannerB. KoelblH. PilchH. HengstlerJ.G. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.Br. J. Cancer200796224124710.1038/sj.bjc.660353817211474
     [Google Scholar]
  46. KimY.B. HolschneiderC.H. GhoshK. NiebergR.K. MontzF.J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women.Cancer199779232032710.1002/(SICI)1097‑0142(19970115)79:2<320::AID‑CNCR15>3.0.CO;2‑29010105
     [Google Scholar]
  47. MontaltoF.I. GiordanoF. ChiodoC. MarsicoS. MauroL. SisciD. AquilaS. LanzinoM. PannoM.L. AndòS. De AmicisF. Progesterone receptor B signaling reduces breast cancer cell aggressiveness: role of cyclin-D1/Cdk4 mediating paxillin phosphorylation.Cancers (Basel)2019118120110.3390/cancers1108120131426542
     [Google Scholar]
  48. Finlay-SchultzJ. GillenA.E. BrechbuhlH.M. IvieJ.J. MatthewsS.B. JacobsenB.M. BentleyD.L. KabosP. SartoriusC.A. Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III.Cancer Res.201777184934494610.1158/0008‑5472.CAN‑16‑354128729413
     [Google Scholar]
  49. XieJ. LiD.W. ChenX.W. WangF. DongP. Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells.Oncol. Lett.20136123223810.3892/ol.2013.132123946810
     [Google Scholar]
  50. a MondalS.K. AhmedM.T. JinkaS. SarkarS. ShuklaR. BanerjeeR. Progesterone-Cationic Lipid Conjugate-Based Self-Aggregates for Cancer Cell-Selective Uptake through Macropinocytosis and the Antitumour Effect.Mol. Pharm.20232062822283510.1021/acs.molpharmaceut.2c0088737134112
     [Google Scholar]
  51. b Tanveer AhmedM. SarkarS. ShuklaR. BanerjeeR. Etoposide-Entrapped Progesterone-Cationic Lipid Nanoaggregates as Selective Therapeutics against Etoposide-Resistant Colorectal Cancer Cells.ChemBioChem20232412e20220065010.1002/cbic.20220065036905093
     [Google Scholar]
  52. FeldmanD. KrishnanA.V. SwamiS. GiovannucciE. FeldmanB.J. The role of vitamin D in reducing cancer risk and progression.Nat. Rev. Cancer201414534235710.1038/nrc369124705652
     [Google Scholar]
  53. MehtaR.G. PengX. AlimirahF. MurilloG. MehtaR. Vitamin D and breast cancer: Emerging concepts.Cancer Lett.201333419510010.1016/j.canlet.2012.10.03423142286
     [Google Scholar]
  54. BrożynaA.A. SlominskiR.M. NedoszytkoB. ZmijewskiM.A. SlominskiA.T. Vitamin D signaling in psoriasis: Pathogenesis and therapy.Int. J. Mol. Sci.20222315857510.3390/ijms2315857535955731
     [Google Scholar]
  55. a SasakiH. MasunoH. KawasakiH. YoshiharaA. NumotoN. ItoN. IshidaH. YamamotoK. HirataN. KandaY. KawachiE. KagechikaH. TanataniA. Lithocholic acid derivatives as potent vitamin D receptor agonists.J. Med. Chem.202164151652610.1021/acs.jmedchem.0c0142033369416
     [Google Scholar]
  56. b MakishimaM. LuT.T. XieW. WhitfieldG.K. DomotoH. EvansR.M. HausslerM.R. MangelsdorfD.J. Vitamin D receptor as an intestinal bile acid sensor.Science200229655711313131610.1126/science.107047712016314
     [Google Scholar]
  57. NehringJ.A. ZieroldC. DeLucaH.F. Lithocholic acid can carry out in vivo functions of vitamin D.Proc. Natl. Acad. Sci. USA200710424100061000910.1073/pnas.070351210417535892
     [Google Scholar]
  58. ShiZ. WuX. WuC.-Y. SinghS.P. LawT. YamadaD. HuynhM. LiakosW. YangG. FarberJ.M. Bile Acids Improve Psoriasiform Dermatitis through Inhibition of IL-17A Expression and CCL20-CCR6-Mediated Trafficking of T Cells.J Invest Dermatol.202214251381139010.1016/j.jid.2021.10.027
     [Google Scholar]
  59. PrausnitzM.R. LangerR. Transdermal drug delivery.Nat. Biotechnol.200826111261126810.1038/nbt.150418997767
     [Google Scholar]
  60. a WilliamsA.C. BarryB.W. Penetration enhancers.Adv. Drug Deliv. Rev.20126412813710.1016/j.addr.2012.09.03215019749
     [Google Scholar]
  61. b KarandeP. MitragotriS. Enhancement of transdermal drug delivery via synergistic action of chemicals.Biochim. Biophys. Acta Biomembr.20091788112362237310.1016/j.bbamem.2009.08.01519733150
     [Google Scholar]
  62. VoshavarC. Kumar VemulaP. MarepallyS. Topical and transdermal delivery with chemical enhancers and nanoparticles.Imaging Technologies and Transdermal Delivery in Skin Disorders201916920010.1002/9783527814633.ch8
     [Google Scholar]
  63. DitschN. TothB. MayrD. LenhardM. GallwasJ. WeissenbacherT. DanneckerC. FrieseK. JeschkeU. The association between vitamin D receptor expression and prolonged overall survival in breast cancer.J. Histochem. Cytochem.201260212112910.1369/002215541142915522108646
     [Google Scholar]
  64. ThakkarA. WangB. Picon-RuizM. BuchwaldP. InceT.A. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.Breast Cancer Res. Treat.20161571779010.1007/s10549‑016‑3807‑y27120467
     [Google Scholar]
  65. ChristakosS. DhawanP. VerstuyfA. VerlindenL. CarmelietG. VitaminD. metabolism, molecular mechanism of action, and pleiotropic effects.Physiol. Rev.201696136540810.1152/physrev.00014.201526681795
     [Google Scholar]
  66. MurrayA. MaddenS.F. SynnottN.C. KlingerR. O’ConnorD. O’DonovanN. GallagherW. CrownJ. DuffyM.J. Vitamin D receptor as a target for breast cancer therapy.Endocr. Relat. Cancer201724418119510.1530/ERC‑16‑046328213567
     [Google Scholar]
  67. KhazanN. KimK.K. HansenJ.N. SinghN.A. MooreT. SnyderC.W.A. PanditaR. StrawdermanM. FujiharaM. TakamuraY. JianY. BattagliaN. YanoN. TeramotoY. ArnoldL.A. HopsonR. KishorK. NayakS. OjhaD. SharonA. AshtonJ.M. WangJ. MilanoM.T. MiyamotoH. LinehanD.C. GerberS.A. KawarN. SinghA.P. TabdanovE.D. DokholyanN.V. KakutaH. JurutkaP.W. SchorN.F. Rowswell-TurnerR.B. SinghR.K. MooreR.G. Identification of a Vitamin-D Receptor antagonist, MeTC7, which inhibits the growth of xenograft and transgenic tumors in vivo.J. Med. Chem.20226586039605510.1021/acs.jmedchem.1c0187835404047
     [Google Scholar]
  68. IkedaU. WakitaD. OhkuriT. ChamotoK. KitamuraH. IwakuraY. NishimuraT. 1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells.Immunol. Lett.2010134171610.1016/j.imlet.2010.07.00220655952
     [Google Scholar]
/content/journals/cis/10.2174/012210299X314913240909071917
Loading
Cationic Lipid Modification of Nuclear Hormone Receptor-Ligands: A Strategy for Developing a New Class of Targeted Anticancer Therapeutics
Curr. Indian Sci. 2, e2210299X314913 (2024); https://doi.org/10.2174/012210299X314913240909071917
/content/journals/cis/10.2174/012210299X314913240909071917
/content/journals/cis/10.2174/012210299X314913240909071917
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Anticancer treatment; Cationic lipid; Estrogen receptor,; Nanotherapeutics; Nuclear hormone receptor; Targeted therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test